Adicet Bio(ACET)
Focus: Adicet Bio is a Boston-based public biotech focused on off-the-shelf CAR-T immunotherapies for oncology and autoimmune diseases. The company is in clinical-stage development with recent positive early data in lupus.
Profile data last refreshed 14h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
1+12 this month
Growing — net +12 jobs in 30d
16 jobs added vs 4 removed. Steady team buildout.
Should You Work at Adicet Bio?
AI assessmentAdicet Bio is a promising but cash-constrained clinical-stage biotech with emerging CAR-T validation; career fit depends on tolerance for restructuring risk and equity upside ambition.
Why Work Here
- Recent clinical momentum: prula-cel showing early promise in lupus with media coverage across BioPharma Dive and Fierce Biotech (Sept-Oct 2026)
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Adicet Bio
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.